Results 121 to 130 of about 910,008 (206)

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Oncotarget, 2018
Merestinib is an oral multi-kinase inhibitor targeting a limited number of oncokinases including MET, AXL, RON and MKNK1/2. Here, we report that merestinib inhibits neurotrophic receptor tyrosine kinases NTRK1/2/3 which are oncogenic drivers in tumors bearing NTRK fusion resulting from chromosomal rearrangements.
Konicek, Bruce W., Capen, Andrew R., Credille, Kelly M., Ebert, Philip J., Falcon, Beverly L., Heady, Gary L., Patel, Bharvin K.R., Peek, Victoria L., Stephens, Jennifer R., Stewart, Julie A., Stout, Stephanie L., Timm, David E., Um, Suzane L., Willard, Melinda D., Wulur, Isabella H., Zeng, Yi, Wang, Yong, Walgren, Richard A., Betty Yan, Sau-Chi   +18 more
openaire   +3 more sources

Inelastic production of J/ψ mesons in photoproduction and deep inelastic scattering at HERA [PDF]

, 2010
A measurement is presented of inelastic photo- and electroproduction of J/ψ mesons in ep scattering at HERA. The data were recorded with the H1 detector in the period from 2004 to 2007. Single and double differential cross sections are determined and the
Egli, S, et al, Grab, C, H1 Collaboration, Müller, K, Nowak, K, Truöl, P, Zimmermann, T   +7 more
core   +1 more source

Melanoma: Pathogenesis and Targeted Therapy

MedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Yu Jiang   +5 more
wiley   +1 more source

Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project [PDF]

, 2022
INTRODUCTION: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Limited data exist on the overall survival (OS) of patients with tumors with NTRK gene fusions and on the co-occurrence of NTRK fusions ...
Bazhenova, Lyudmila, Bridgewater, John, Bruno, Amanda, Fellous, Marc, Flach, Clare, Jiao, Xiaolong, Kamburov, Atanas, Keating, Karen, Parimi, Mounika, Pereira, Mariana Buongermino, Reeves, John A, Schmitz, Arndt A, Stratford, Jeran, Zong, Jihong   +13 more
core  

Comparative Analysis of a Dual DNA–RNA Panel and a DNA‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database

Cancer Science, Volume 117, Issue 1, Page 156-168, January 2026.
Dual DNA–RNA panel with matched tumor–normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma. ABSTRACT Next‐generation sequencing‐based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor‐only DNA panels from single ...
Eiji Nakata, Kiichiro Ninomiya, Tatsunori Osone, Daisuke Ennishi, Shuta Tomida, Tomohiro Fujiwara, Toshiyuki Kunisada, Mashu Futagawa, Akira Hirasawa, Shinichi Toyooka, Toshifumi Ozaki   +10 more
wiley   +1 more source

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report

BMC Pulmonary Medicine, 2021
Background The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor.
Lei Zhang, Huanhuan Liu, Ye Tian, Huina Wang, Xueying Yang   +4 more
doaj   +1 more source

TRK fusion positive cancers:From first clinical data of a TRK inhibitor to future directions [PDF]

, 2020
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK
D'Angelo, Alberto, De Logu, Francesco, Massi, Daniela, Mini, Enrico, Nobili, Stefania, Roviello, Giandomenico, Sciortino, Marianna   +6 more
core   +1 more source

Realizing Equitable Precision Oncology via Remote Participation: Japan's First Fully Decentralized Trial (WJOG15221M)

Cancer Science, Volume 117, Issue 1, Page 272-274, January 2026.
WJOG15221M is Japan's first fully remote, investigator‐initiated oncology trial, successfully enrolling 28 patients—36% remotely—by integrating trial access into the national CGP program and leveraging existing healthcare infrastructure without new digital tools.
Hiroya Taniguchi, Toshiki Masuishi, Tomoki Sakakida, Takatsugu Ogata, Nobumasa Mizuno, Masashi Ando, Kei Muro, Hidetoshi Hayashi   +7 more
wiley   +1 more source

The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis

Pathology International, Volume 76, Issue 1, January 2026.
We identified both known and novel gene fusions in thyroid neoplasia, including several previously reported only in nonthyroid malignancies. Gene fusion–positive tumors were significantly (p < 0.001, annotated as ***) associated with florid chronic lymphocytic thyroiditis, unlike tumors driven by somatic mutations or copy number variations.
Maaia Margo Jentus, Tom van Wezel, Dina Ruano, Marieke Snel, Abbey Schepers, Stijn Crobach, Hans Morreau   +6 more
wiley   +1 more source

Étude de la production des quarkonia J/Ψ, Ψ' et ϒ en fonction de la multiplicité de traces chargées dans les collisions proton-proton à 8 TeV au LHC avec l'expérience ALICE [PDF]

, 2015
One of the main goal of the ALICE experiment at LHC is the study of quarkonia. This particles are probe of the quark-gluon plasma (QGP). Quarkonia production rate is sensitive to the formation of the QGP.
Noyer , Hugues
core